| Returns | 1W : -0.1% , 1M : -1.1%,1Y : 6.7% |
| Peers & Returns | 1W | 1M | 1Y |
| WOCKHARDT | -0.1% | -1.1% | 6.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -5.7% | -9.7% | 11.1% |
| DRREDDYS LABORATORIES | -1.9% | -5.8% | 76.4% |
| DIVIS LABORATORIES | 3.3% | 3.1% | 77.1% |
| CIPLA | 1.2% | -2.7% | 61% |
| PIRAMAL ENTERPRISES | -8.5% | -3% | -23.1% |
| LUPIN | -5.7% | -9.8% | 25.9% |
| AUROBINDO PHARMA | -1.5% | -3% | 62.9% |
| TORRENT PHARMACEUTICALS | -3.4% | -8.4% | 40.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
181.12 5.18 2.95 - |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-18% -5% -11% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
1.94 1.58 1.41 1.64 |
1.22 1.28 1.33 1.28 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
37.12 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
9.48% 79.86% 121.63% 122.82% |
-17.28% 17.82% 92.36% 101.05% |
| QtrlyTrend |
6
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
